Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

(2020) Jeremy S. Abramson et al.   BLOOD

Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis

(2020) Magid Awadalla et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas

(2020) Peter A. Riedell et al.   Therapeutic Advances in Hematology

Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic

(2020) Veronika Bachanova et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma

(2020) Jennifer M. Logue et al.   HAEMATOLOGICA

CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial

(2020) Nirali N. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

(2020) Loretta J. Nastoupil et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel).

(2020) Paolo Strati et al.   JOURNAL OF CLINICAL ONCOLOGY

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

(2020) Michael Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

How we prevent infections in patients receiving CD19-targeted chimeric antigen receptor T-cells for B-cell malignancies

(2020) Joshua A. Hill et al.   BLOOD

Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients

(2020) Kazusa Ishii et al.   JOURNAL OF CLINICAL INVESTIGATION

Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy

(2019) Lara L. Riegler et al.   Therapeutics and Clinical Risk Management

Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy

(2019) Utkarsh H. Acharya et al.   Expert Review of Hematology

CAR T-cell associated neurotoxicity: Mechanisms, clinicopathologic correlates, and future directions

(2019) Bradley D Hunter et al.   JNCI-Journal of the National Cancer Institute

THE CARDIOVASCULAR EFFECTS OF CHIMERIC ANTIGEN RECEPTOR T-CELLS

(2019) Raza M. Alvi et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Early and late hematologic toxicity following CD19 CAR-T cells

(2019) Shalev Fried et al.   BONE MARROW TRANSPLANTATION

Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T-cells

(2019) Philipp Karschnia et al.   BLOOD

The response to lymphodepletion impacts PFS in aggressive non-Hodgkin lymphoma patients treated with CD19 CAR-T cells

(2019) Alexandre V. Hirayama et al.   BLOOD

Cytopenias after Chimeric Antigen Receptor T-Cells (CAR-T) Infusion; Patterns and Outcomes

(2019) Andrew Shaefer et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Toxicities of CD19 CAR-T cell immunotherapy

(2019) Alexandre V. Hirayama et al.   AMERICAN JOURNAL OF HEMATOLOGY

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

(2019) Noopur Raje et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tisagenlecleucel CAR-T Cell Therapy in Secondary CNS Lymphoma

(2019) Matthew J. Frigault et al.   BLOOD

Managing the toxicities of CAR T‐cell therapy

(2019) Sattva S. Neelapu   HEMATOLOGICAL ONCOLOGY

Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells

(2019) Ana Cordeiro et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

CAR-T – and a side order of IgG, to go? – Immunoglobulin replacement in patients receiving CAR-T cell therapy

(2019) Joshua A. Hill et al.   BLOOD REVIEWS

Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy

(2019) Hamza Hashmi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Successful anti‐CD19 CAR T‐cell therapy in HIV‐infected patients with refractory high‐grade B‐cell lymphoma

(2019) Jeremy S. Abramson et al.   CANCER

Management Principles Associated With Cytokine Release Syndrome

(2019) Brittney Baer et al.   Seminars in Oncology Nursing

Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy

(2019) Julia Ruark et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy

(2019) Hui Luo et al.   Journal for ImmunoTherapy of Cancer

Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)

(2019) Raza M. Alvi et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)

(2019) George R. Nahas et al.   LEUKEMIA & LYMPHOMA

Subcutaneous immunoglobulin replacement following CD19‐specific chimeric antigen receptor T‐cell therapy for B‐cell acute lymphoblastic leukemia in pediatric patients

(2019) Danielle E. Arnold et al.   PEDIATRIC BLOOD & CANCER

Cardiac Profile of Chimeric Antigen Receptor T Cell Therapy in Children: A Single-Institution Experience

(2018) Danielle S. Burstein et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Chimeric Antigen Receptor T Cell Therapy and the Kidney

(2018) Kenar D. Jhaveri et al.   Clinical Journal of the American Society of Nephrology

Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts

(2018) Ping-Pin Zheng et al.   DRUG DISCOVERY TODAY

Fludarabine and neurotoxicity in engineered T-cell therapy

(2018) Kate L. Lowe et al.   GENE THERAPY

Age-associated distribution of normal B-cell and plasma cell subsets in peripheral blood

(2018) Elena Blanco et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel

(2018) David Porter et al.   Journal of Hematology & Oncology

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

(2018) Syed S. Mahmood et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells

(2018) Margherita Norelli et al.   NATURE MEDICINE

Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'

(2018) Sattva S. Neelapu et al.   Nature Reviews Clinical Oncology

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

(2018) Jae H. Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome

(2018) Robert Q. Le et al.   ONCOLOGIST

Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)

(2018) Bianca D. Santomasso et al.   Cancer Discovery

People

(2018)   Cancer Discovery

Cytokine release syndrome

(2018) Alexander Shimabukuro-Vornhagen et al.   Journal for ImmunoTherapy of Cancer

Neurotoxicity after CTL019 in a Pediatric and Young Adult Cohort

(2018) Jacqueline S. Gofshteyn et al.   ANNALS OF NEUROLOGY

Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema

(2018) Matthew Torre et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Fourth Universal Definition of Myocardial Infarction (2018)

(2018) Kristian Thygesen et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Chimeric Antigen Receptor T-Cell Therapy

(2018) Ndiya Ogba et al.   Journal of the National Comprehensive Cancer Network

Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy

(2018) Kris M. Mahadeo et al.   Nature Reviews Clinical Oncology

Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function

(2018) Alexander I. Salter et al.   Science Signaling

The biological basis and clinical symptoms of CAR-T therapy-associated toxicites

(2018) Aleksei Titov et al.   Cell Death & Disease

Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities

(2018) Bhagirathbhai R. Dholaria et al.   BIODRUGS

Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy

(2018) Noelle Frey et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells

(2018) Daniel W Lee et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts

(2018) Rosalie M. Sterner et al.   BLOOD

Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management

(2018) Jennifer N. Brudno et al.   BLOOD REVIEWS

Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy

(2018) Kevin A. Hay   BRITISH JOURNAL OF HAEMATOLOGY

Inflammatory and Infectious Syndromes Associated with Cancer Immunotherapies

(2018) Jay A Fishman et al.   CLINICAL INFECTIOUS DISEASES

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

(2018) Wan-Hong Zhao et al.   Journal of Hematology & Oncology

NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018

(2018) Michael B. Streiff et al.   Journal of the National Comprehensive Cancer Network

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

(2018) Frederick L Locke et al.   LANCET ONCOLOGY

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia

(2018) Melanie D. Whittington et al.   JAMA Pediatrics

Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity

(2018) Lars Michel et al.   Journal of Thoracic Disease

Update on the use of immunoglobulin in human disease: A review of evidence

(2017) Elena E. Perez et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib

(2017) Cameron J. Turtle et al.   JOURNAL OF CLINICAL ONCOLOGY

The Effectiveness of Trivalent Inactivated Influenza Vaccine in Children with Acute Leukemia

(2017) April Sykes et al.   JOURNAL OF PEDIATRICS

The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy

(2017) Felipe Bedoya et al.   MOLECULAR THERAPY

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

(2017) Terry J Fry et al.   NATURE MEDICINE

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

(2017) Sattva S. Neelapu et al.   Nature Reviews Clinical Oncology

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

(2017) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hypogammaglobulinemia due to CAR T-cell therapy

(2017) Andrew Doan et al.   PEDIATRIC BLOOD & CANCER

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

(2017) Donald M. O’Rourke et al.   Science Translational Medicine

Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells

(2017) Juliane Gust et al.   Cancer Discovery

HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma

(2017) Nabil Ahmed et al.   JAMA Oncology

Efficacy and toxicity management of CAR-T-cell immunotherapy: a matter of responsiveness control or tumour-specificity?

(2016) Vanesa Alonso-Camino et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma

(2016) S. A. Ali et al.   BLOOD

Toxicities of chimeric antigen receptor T cells: recognition and management

(2016) Jennifer N. Brudno et al.   BLOOD

Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy

(2016) V. G. Bhoj et al.   BLOOD

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

(2016) Mervyn Singer et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

(2016) Cameron J. Turtle et al.   JOURNAL OF CLINICAL INVESTIGATION

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease

(2016) Jennifer N. Brudno et al.   JOURNAL OF CLINICAL ONCOLOGY

Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy

(2016) Yongxian Hu et al.   Journal of Hematology & Oncology

Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy

(2016) Fang Chen et al.   JOURNAL OF IMMUNOLOGICAL METHODS

International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer

(2016) Dominique Farge et al.   LANCET ONCOLOGY

Medical management of side effects related to CAR T cell therapy in hematologic malignancies

(2016) Manjusha Namuduri et al.   Expert Review of Hematology

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

(2016) D. T. Teachey et al.   Cancer Discovery

Clinical and In Vitro Studies on Impact of High-Dose Etoposide Pharmacokinetics Prior Allogeneic Hematopoietic Stem Cell Transplantation for Childhood Acute Lymphoblastic Leukemia on the Risk of Post-Transplant Leukemia Relapse

(2015) Joanna Sobiak et al.   ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS

Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy

(2015) D. Cardinale et al.   CIRCULATION

2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

(2015) Marco Roffi et al.   EUROPEAN HEART JOURNAL

Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

(2015) Nabil Ahmed et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

(2015) James N. Kochenderfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Serum uric acid and the risk of cardiovascular and renal disease

(2015) Claudio Borghi et al.   JOURNAL OF HYPERTENSION

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

The pharmacology of second-generation chimeric antigen receptors

(2015) Sjoukje J. C. van der Stegen et al.   NATURE REVIEWS DRUG DISCOVERY

Treatment of hemophagocytic lymphohistiocytosis in adults

(2015) P. La Rosee   Hematology-American Society of Hematology Education Program

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD

Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies

(2014) Shannon L. Maude et al.   CANCER JOURNAL

Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

(2014) Juan Carlos Plana et al.   JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

Immunoglobulin Replacement Therapy in Secondary Hypogammaglobulinemia

(2014) Nicolò Compagno et al.   Frontiers in Immunology

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

(2013) J. N. Kochenderfer et al.   BLOOD

Cornell Assessment of Pediatric Delirium

(2013) Chani Traube et al.   CRITICAL CARE MEDICINE

Etoposide Selectively Ablates Activated T Cells To Control the Immunoregulatory Disorder Hemophagocytic Lymphohistiocytosis

(2013) T. S. Johnson et al.   JOURNAL OF IMMUNOLOGY

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

(2013) R. J. Brentjens et al.   Science Translational Medicine

European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN

(2013) D. Engelhard et al.   Transplant Infectious Disease

T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans

(2013) M. V. Maus et al.   Cancer Immunology Research

The myth of the second remission of acute leukemia in the adult

(2012) S. J. Forman et al.   BLOOD

Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines

(2011) M. Mandala et al.   ANNALS OF ONCOLOGY

The Tumor Lysis Syndrome

(2011) Scott C. Howard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines

(2010) D. Bovelli et al.   ANNALS OF ONCOLOGY

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

(2010) J. N. Kochenderfer et al.   BLOOD

Late relapses in acute myeloid leukemia: analysis of characteristics and outcome

(2010) Dushyant Verma et al.   LEUKEMIA & LYMPHOMA

Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial

(2010) Renier Brentjens et al.   MOLECULAR THERAPY

Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective

(2009) Marcie Tomblyn et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses

(2009) Ken M Kunisaki et al.   LANCET INFECTIOUS DISEASES

Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model

(2008) P. Montesinos et al.   HAEMATOLOGICA